According to Fortune Business Insights, the global antimicrobial susceptibility testing market was valued at USD 4.73 billion in 2025 and is expected to grow from USD 4.97 billion in 2026 to USD 7.38 billion by 2034, registering a CAGR of 5.07% during the forecast period. The market is expanding steadily due to the rising prevalence of antimicrobial resistance (AMR), increasing incidence of infectious diseases, growing adoption of rapid diagnostic technologies, and heightened focus on antimicrobial stewardship programs. Continuous advancements in automated testing systems and increasing investments in healthcare infrastructure are further driving the demand for antimicrobial susceptibility testing solutions across hospitals, diagnostic laboratories, and research institutions worldwide.
The increasing burden of infectious diseases, growing prevalence of drug-resistant bacteria, and rising investments in diagnostic technologies are among the key factors accelerating market expansion. Hospitals, diagnostic laboratories, pharmaceutical companies, and research institutions are increasingly relying on antimicrobial susceptibility testing to identify effective treatment options and improve patient outcomes.
Antimicrobial susceptibility testing is a laboratory procedure used to determine how effective antibiotics, antifungal agents, or other antimicrobial drugs are against specific microorganisms. The test helps physicians select the most appropriate therapy while minimizing unnecessary antibiotic usage.
With antimicrobial resistance becoming a significant global public health concern, AST has become an essential component of clinical microbiology laboratories. Rapid and accurate testing enables healthcare providers to prescribe targeted therapies, reducing treatment failures and improving infection control.
Antimicrobial resistance has emerged as one of the most pressing healthcare challenges worldwide. Overuse and misuse of antibiotics have accelerated the development of resistant bacterial strains, creating an urgent need for advanced diagnostic solutions.
Healthcare organizations are increasingly adopting antimicrobial susceptibility testing systems to identify resistant pathogens quickly and guide appropriate antibiotic therapy.
The growing number of bacterial, fungal, and hospital-acquired infections continues to fuel demand for diagnostic testing. Conditions such as urinary tract infections, bloodstream infections, respiratory infections, and sepsis require rapid identification of pathogens and their susceptibility profiles.
This increasing disease burden is expected to remain a major driver of market growth throughout the forecast period.
Modern AST platforms incorporate automation, artificial intelligence, molecular diagnostics, and rapid testing technologies to deliver faster and more accurate results.
Automated systems reduce manual errors while improving laboratory efficiency. These technological innovations are enabling healthcare providers to initiate targeted treatments much earlier than traditional culture-based methods.
Governments and healthcare organizations across developed and emerging economies are investing heavily in diagnostic infrastructure. Public health initiatives focused on antimicrobial stewardship programs are further supporting the adoption of antimicrobial susceptibility testing solutions.
Despite strong growth prospects, the antimicrobial susceptibility testing market faces several challenges.
The high cost of automated diagnostic instruments limits adoption among smaller laboratories and healthcare facilities. In addition, stringent regulatory approval processes and the shortage of skilled laboratory professionals continue to impact market expansion.